| Followers | 22 |
| Posts | 2369 |
| Boards Moderated | 1 |
| Alias Born | 09/27/2020 |
Thursday, September 26, 2024 9:23:14 PM
Did you see where I sold part of my NVAX holdings on the latest news and bought back $1.50 lower and gained $9,425 worth of FREE Novavax shares? Lowered my average cost basis from $5.63/share to $5.41 in the process. That's what some claim to be doing on the MONI board. So how are their actions not a P&D but mine are?
Novavax has a short-seller problem. The overall percentage of shares shorted has been heading lower for months, currently around 20-22% of outstanding shares. I don't short stocks and I don't buy on margin. Myself and some other NVAX investors are trying to take advantage of shorting presence by trading a little on the price swings created by these shorts. That's not illegal, and it's not pumping and dumping as you seem to believe. My outlook on Novavax has always been positive, and my outlook doesn't change on a dime like it does with most P&D'ers. Look to your own MONI board for examples.
Educate yourself more and you won't appear uninformed or ignorant in what you post. I'm guessing you don't really care. 🤣
Recent NVAX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/27/2026 12:57:59 AM
- Novavax shares gain after Matrix-M adjuvant licensing deal with Pfizer • IH Market News • 01/20/2026 02:48:06 PM
- Novavax Announces Entering into a License Agreement with Pfizer • PR Newswire (US) • 01/20/2026 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 11:59:39 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 01:01:06 PM
- Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/07/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2025 09:01:11 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 11/12/2025 09:17:57 PM
- Novavax to Participate in Jefferies London Healthcare Conference • PR Newswire (US) • 11/12/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2025 01:00:22 PM
- Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights • PR Newswire (US) • 11/06/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 12:47:47 PM
- Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment • PR Newswire (US) • 11/04/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2025 11:02:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/30/2025 08:30:19 PM
- Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 • PR Newswire (US) • 10/30/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/22/2025 11:00:50 AM
- Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy • PR Newswire (US) • 10/22/2025 11:00:00 AM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 10/14/2025 11:45:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2025 11:00:33 AM
- Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment • PR Newswire (US) • 10/07/2025 11:00:00 AM
- Novavax Announces Progress on Sanofi Agreement • PR Newswire (US) • 09/30/2025 01:01:00 PM
- Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment • PR Newswire (US) • 09/04/2025 12:00:00 PM
- Novavax to Participate in the Cantor Global Healthcare Conference • PR Newswire (US) • 09/03/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2025 08:40:29 PM
Closing the Intent-to-Execution Gap May Define Next Wave of AI Investment • WLDS • Feb 17, 2026 9:00 AM
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A • ARWR • Feb 17, 2026 9:00 AM
UPDATE: Hydromer, Inc. Announces Expansion Into High-Speed Automated Coating and UV Cure Equipment Manufacturing • HYDI • Feb 10, 2026 10:58 AM
MedWell Ai Executes Letter Of Intent To Create America's First Vertically Integrated Regenerative Wellness Eco-System • MWAI • Feb 10, 2026 8:45 AM
LaFleur Minerals Reports Assay Results Highlighting 2.05 g/t Au over 158.25 metres, Confirming Strong Gold Continuity at Swanson Gold Project • LFLRF • Feb 5, 2026 5:29 AM
DRCR Begins Rollout of New Business Model • DRCR • Feb 4, 2026 12:42 PM
